Oculis to Present at Upcoming March Investor Conference
05. März 2025 04:00 ET
|
Oculis Holding AG
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
03. März 2025 03:18 ET
|
Oculis Holding AG
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Attachments
...
Oculis greinir frá umframeftirspurn og öðrum niðurstöðum 100 milljón USD útboðs á almennum hlutum
13. Februar 2025 19:40 ET
|
Oculis Holding AG
ZUG, Sviss, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) („Oculis“ eða „félagið“), alþjóðlegt líftæknilyfjafyrirtæki með áherslu á nýsköpun til að meðhöndla...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
13. Februar 2025 19:40 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
13. Februar 2025 19:39 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated
07. Februar 2025 18:35 ET
|
Oculis Holding AG
ZUG, Switzerland, Feb. 08, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting of earnout shares and associated removal of restrictions on these ordinary shares.
...
Oculis updates share capital for its existing at-the-market offering program
31. Januar 2025 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares...
Oculis Publishes Notification of Major Changes in Voting Rights
21. Januar 2025 16:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights.
Attachment
Notification of Major Changes in Voting...
Oculis Publishes Notification of Major Changes in Voting Rights
20. Januar 2025 17:00 ET
|
Oculis Holding AG
ZUG, Switzerland, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights.
Attachment
Notification of Major Changes in Voting...
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
06. Januar 2025 03:53 ET
|
Oculis Holding AG
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential...